What is Neuland Laboratories Ltd's PE ratio?

Neuland Laboratories Ltd trades at a P/E ratio of 65.90.

What is Neuland Laboratories Ltd's market cap?

Neuland Laboratories Ltd's market capitalisation is ₹23,794 Cr.

When are Neuland Laboratories Ltd's next results?

Neuland Laboratories Ltd's next earnings date is 5 Aug '26.

What is Neuland Laboratories Ltd's ROE?

Neuland Laboratories Ltd's return on equity (ROE) is 21.2%.

What sector is Neuland Laboratories Ltd in?

Neuland Laboratories Ltd (NEULANDLAB) is classified in the Healthcare sector (Pharmaceuticals).

Healthcare · Pharmaceuticals

Neuland Laboratories Ltd (NEULANDLAB)

₹18,546.00

Mkt cap

₹23,794 Cr

P/E ratio

65.90

P/B

12.69

Div yield

0.18%

ROE

21.20%

ROCE

26.50%

EPS (TTM)

₹281.43

Book value

₹1,461

52W range

11,555–19,542

Sector

Healthcare

Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets. [1]

NSE NEULANDLABBSE 524558www.neulandlabs.com

Health check

Constructive

ValuationExpensive

ProfitabilityStrong

GrowthModerate

TechnicalsBullish

52-week range

−5.10% from high

₹18,546

₹11,555+60.50% from low₹19,542

Current

₹18,546.00

Prev close

₹18,525.00

Day

+0.11%

Price performance

+0.11%

−2.13%

+3.26%

+28.75%

+36.56%

+27.88%

YTD

+21.41%

Financials

F

Revenue, profit & margin

P/E ratio

65.9×

NEULANDLAB is 94% above the sector median of 34.0×

NEULANDLAB65.9×

Sector median34.0×

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Sales	407	363	418	393	385	440	311	398	328	293	514	440	776
Expenses	287	266	280	272	278	316	249	311	277	258	359	363	469
Operating Profit	120	97	137	121	107	123	62	87	51	34	156	77	307
OPM %	29%	27%	33%	31%	28%	28%	20%	22%	16%	12%	30%	18%	40%
Other Income	8	2	3	2	5	25	4	60	7	8	2	8	12
Interest	4	2	4	4	4	3	1	2	2	5	5	7	7
Depreciation	13	14	15	15	16	16	16	16	17	20	23	24	25
Profit before tax	110	83	122	104	92	130	49	128	39	18	129	54	287
Tax %	23%	26%	27%	22%	27%	25%	34%	20%	29%	21%	25%	26%	26%
Net Profit	85	62	89	81	68	98	33	102	28	14	97	41	213
EPS in Rs	65.89	48.23	69.56	63.44	52.66	76.28	25.60	79.18	21.68	10.83	75.49	31.62	165.76
Raw PDF

Earnings

EResults dates & reactions

Next results

5 Aug '26scheduled

Fresh quarters land in the Financials table above, tagged NSE until screener catches up.

Avg earnings-day move −1.53% · closed higher next day 19 of last 61

	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	Q3FY26	Q4FY26
Broadcast	3 Aug '23◦	7 Nov '23◦	8 Feb '24◦	10 May '24◦	1 Aug '24◦	6 Nov '24	10 Feb '25◦	16 May '25	31 Jul '25◦	7 Nov '25◦	9 Feb '26◦	12 May '26◦
Earnings day	+5.33%	+7.02%	+3.71%	−15.11%	+18.08%	−10.68%	−6.85%	−6.77%	−1.99%	+1.55%	−2.79%	−2.98%
+1 day	+7.85%	+14.02%	−1.14%	−13.56%	+16.84%	−13.11%	−7.00%	−5.41%	−1.49%	−3.61%	−5.04%	−1.90%
+5 days	+15.62%	+14.86%	+9.53%	−12.81%	+22.76%	−7.52%	−24.85%	−5.93%	−1.37%	−2.70%	−1.59%	−2.23%
+15 days	+7.69%	+16.41%	+11.35%	−14.36%	+26.85%	+5.37%	−19.31%	+9.87%	+1.85%	−7.01%	−8.02%	−0.84%
+30 days	+3.62%	+10.88%	−1.11%	+2.83%	+36.47%	−12.40%	−17.75%	+2.20%	+22.14%	−11.74%	−12.92%	+5.63%
Filing	XBRL	XBRL	XBRL	XBRL	XBRL	XBRL	XBRL	XBRL	XBRL	XBRL	XBRL	XBRL

Corporate actions

CLast 6 months

Kind	Value	Ex-date	Record
dividend Dividend - Rs 34 Per Share	34.00	24 Jul '26	24 Jul '26

Shareholding

Sas of Jun 2026

32.62%Promoter

Promoters32.62%0.01

FIIs21.08%0.62

DIIs16.52%0.68

Public29.79%1.29

Government0.00%

Ownership trend

Peers

P8 companies

Valuation vs quality

P/E × ROCE · bubble = market cap

Name	CMP	P/E	Mkt Cap	Div Yld	NP Qtr	Qtr Profit Var	Sales Qtr	Qtr Sales Var	ROCE
Sun Pharma.Inds.	₹1,941.10	37.48	4,65,735	0.82%	2,710	+13.58%	14,612	+12.76%	20.53%
Divi's Lab.	₹7,248.50	73.36	1,92,425	0.41%	751	+13.44%	2,831	+9.52%	21.97%
Torrent Pharma.	₹4,961.50	86.11	1,88,720	0.77%	364	−20.58%	4,197	+41.84%	15.19%
Cipla	₹1,410.60	31.84	1,13,955	0.92%	786	−39.19%	7,119	+2.33%	15.49%
Zydus Lifesci.	₹1,108.70	20.38	1,10,593	0.09%	1,341	+21.92%	7,587	+16.22%	21.14%
Lupin	₹2,370.50	19.06	1,08,387	0.76%	1,469	+101.49%	7,475	+31.89%	29.93%
Mankind Pharma	₹2,507.20	51.44	1,03,546	0.04%	559	+34.23%	3,443	+11.81%	13.53%
Neuland Labs.	₹18,546.00	65.89	23,794	0.18%	213	+664.72%	776	+136.40%	26.47%
Median: 157 Co.	₹432.05	34.03	1,978	0.10%	15	+28.10%	176	+17.66%	15.10%

Filings

D

Annual reports15

Financial Year 2026bse Financial Year 2025bse Financial Year 2024bse Financial Year 2023bse Financial Year 2022bse Financial Year 2021bse Financial Year 2020bse Financial Year 2019bse Financial Year 2018bse Financial Year 2017bse Financial Year 2016bse Financial Year 2015bse Financial Year 2014bse Financial Year 2013nse Financial Year 2013bse

Credit ratings6

Rating update 13 Julfitch Rating update 20 Jun 2025crisil Rating update 7 May 2025fitch Rating update 10 Mar 2025fitch Rating update 27 Mar 2024crisil Rating update 14 Feb 2024fitch

Announcements5

Board Meeting Intimation for Considering And Approving The Unaudited Financial Results Of The Company For The Quarter Ended June 30, 2026 20 Jul - Board meeting on Aug 5, 2026 to approve Q1 FY27 unaudited standalone and consolidated results.Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 20 Jul Announcement under Regulation 30 (LODR)-Credit Rating 13 Jul - India Ratings affirmed Neuland Laboratories' bank loan rating at IND A+/Positive and IND A1.Announcement under Regulation 30 (LODR)-Newspaper Publication 10 Jul - Newspaper Publication regarding dispatch of notice of 42nd Annual General Meeting and Integrated Annual Report for FY 2025-26 Letter To The Shareholders Of The Company In Relation To The Notice Of 42Nd Annual General Meeting And Integrated Annual Report Of The Company For FY 2025-26 9 Jul - 42nd AGM on August 4, 2026 via VC/OAVM; annual report and notice sent to shareholders.